{"id":"W2162225483","doi":"10.1002/cncr.24864","title":"Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America","year":2010,"lang":"en","type":"article","venue":"Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; McGill University Health Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sorafenib; Renal cell carcinoma; Rash; Internal medicine; Population; Adverse effect; Expanded access; Surgery; Oncology; Bevacizumab; Kidney cancer; Hepatocellular carcinoma; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002052965,0.0001904133,0.0003612218,0.0002266074,0.0002687743,0.0005116331,0.0002982017,0.0003423876,0.00166286],"category_scores_gemma":[0.002209414,0.000116752,0.0003653395,0.0003870973,0.0003725197,0.0002767895,0.0002863164,0.0006648197,0.0002649053],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001330458,"about_ca_system_score_gemma":0.001771672,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005638486,"about_ca_topic_score_gemma":0.008404636,"domain_scores_codex":[0.9986631,0.0007831604,0.00004652157,0.0001266267,0.0002740108,0.0001065822],"domain_scores_gemma":[0.9968364,0.0006366459,0.0008880418,0.000129469,0.0006720199,0.000837373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.142513,0.01626153,0.3375331,0.0007674432,0.001831453,0.0007512847,0.0009151998,0.003292091,0.01596054,0.0005342799,0.02570516,0.4539349],"study_design_scores_gemma":[0.03377995,0.06730597,0.8651218,0.0001986162,0.001128743,0.001110258,0.0003560726,0.002118178,0.004777082,0.0002018778,0.02386219,0.00003927662],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908596,0.002527129,0.0002373718,0.0007278797,0.00003083317,0.000232525,0.000934871,0.00004518058,0.004404685],"genre_scores_gemma":[0.9942526,0.00118713,0.0003899251,0.000564802,0.00007333011,0.0002021082,0.002264201,0.00001293195,0.001052851],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005638486,"threshold_uncertainty_score":0.01121134,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01903789165889219,"score_gpt":0.3025669710936259,"score_spread":0.2835290794347337,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}